# First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss

> **NCT07637981** · PHASE2 · RECRUITING · sponsor: **Dendrogenix** · enrollment: 24 (estimated)

## Conditions studied

- Age-related Hearing Loss

## Interventions

- **DRUG:** DX243
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07637981
- **Lead sponsor:** Dendrogenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-13
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637981, "First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*